TRCT
PROK icon

Tower Research Capital (TRC)’s ProKidney PROK Stock Holding History

Tower Research Capital (TRC)’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.6K Buy
20,439
+20,424
+136,160% +$43.3K ﹤0.01% 3012
2025
Q4 		$34 Sell
15
-4,176
-100% -$11K ﹤0.01% 5085
2025
Q3 		$10.1K Sell
4,191
-51,211
-92% -$136K ﹤0.01% 3995
2025
Q2 		$32.8K Buy
55,402
+39,649
+252% +$30.9K ﹤0.01% 3333
2025
Q1 		$13.8K Buy
15,753
+4,996
+46% +$6.93K ﹤0.01% 3332
2024
Q4 		$18.2K Buy
10,757
+5,658
+111% +$10.2K ﹤0.01% 3267
2024
Q3 		$9.79K Sell
5,099
-7,915
-61% -$18K ﹤0.01% 3833
2024
Q2 		$32K Sell
13,014
-1,144
-8% -$3.07K ﹤0.01% 3433
2024
Q1 		$23.2K Buy
14,158
+1,913
+16% +$2.81K ﹤0.01% 2870
2023
Q4 		$21.8K Buy
12,245
+4,890
+66% +$10.5K ﹤0.01% 3591
2023
Q3 		$33.7K Buy
7,355
+4,891
+198% +$46.8K ﹤0.01% 2919
2023
Q2 		$27.6K Sell
2,464
-1,992
-45% -$21.2K ﹤0.01% 3102
2023
Q1 		$50K Buy
4,456
+2,211
+98% +$23.5K ﹤0.01% 2498
2022
Q4 		$15K Buy
2,245
+1,160
+107% +$11.1K ﹤0.01% 3444
2022
Q3 		$10K Buy
1,085
+432
+66% +$3.76K ﹤0.01% 4565
2022
Q2 		$6K Buy
+653
New +$6.46K ﹤0.01% 4945
2022
Q1 		– Sell
-536
Closed -$5K – 6458
2021
Q4 		$5K Buy
+536
New +$5.3K ﹤0.01% 5184

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s PROK Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its ProKidney (PROK) stake by 136,160% in Q1 2026, buying an estimated $43.3K and bringing the position to 20,439 shares worth $36.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Tower Research Capital (TRC) first reported a position in PROK in Q4 2021 and has held it in 17 quarters since. The position peaked at $50K in Q1 2023. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Tower Research Capital (TRC) held 20,439 shares of ProKidney worth $36.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 20,424 ProKidney shares in Q1 2026, an estimated $43.3K.
  • ProKidney made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3012 holding.
  • Tower Research Capital (TRC) first reported a position in ProKidney in Q4 2021 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s ProKidney position peaked at $50K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.